期刊文献+

间充质干细胞联合单倍体异基因造血干细胞移植治疗27例重型再生障碍性贫血临床疗效 被引量:18

Clinical effect of cotransplantation of haploidentical hematopoietic stem cells and umbilical cord mesenchymal stem cells for patients with severe aplastic anemia
下载PDF
导出
摘要 目的 回顾性分析重型再生障碍性贫血(severe aplastic anemia,SAA)行脐带间充质干细胞(umbilical cord mesenchymal stem cells,UC-MSCs)联合单倍体异基因造血干细胞移植(haploidentical stem cells transplantatio,haplo-HSCT)治疗的临床疗效.方法 总结解放军总医院第一附属医院血液科2007年1月-2013年12月住院收治的27例SAA患者进行UC-MSCs联合haplo-HSCT治疗的资料,观察移植后细胞植入、移植物抗宿主病(graft-versus-host disease,GVHD)发生率及严重程度和2年总生存率(overall survival,OS).结果 干细胞全部植入成功,无MSC回输不良事件发生.白细胞及血小板植入时间分别为12(8~ 21)d及14(10~26)d;Ⅱ~Ⅳ度和Ⅲ/Ⅳ度aGVHD发生率分别为40.7%和22.2%,cGVHD发生率为50.0%,广泛性仅为15.4%;2年OS为76.3%.结论 UC-MSCs联合haplo-HSCT对无全相合亲缘或无关供者的SAA患者疗效可行有效,可作为SAA患者挽救治疗选择. Objective To analyse the clinical effect of cotransplantafion of haploidentical hematopoietic stem cells and umbilical cord mesenchymal stem cells (UC-MSCs) for patients with severe aplastic anemia (SAA). Methods Clinical data about 27 patients with haploidentical stem cells transplantation (haplo-HSCT) in our center from January 2007 to December 2013 were summarized. The engraftment, graft-versus-host disease (GVHD), overall survival (OS), disease/progression-free survival (PFS) and relapse after 2 years were observed. Results All patients given MSCs showed sustained hematopoietic engraftment without any adverse UC-MSC infusion-related reaction. The median times of transplantation of neutrophil 〉 0.50×10^9/L and platelet 〉 20× 10^9/L engraftment were 12.0 days (8-21 days) and 14.0 days (10-26 days), respectively. Grade Ⅱ to IV and Ⅲ/ Ⅳ aGVHD was observed in 11 of 27 patients (40.7%) and 6 of 27 cases (22.2%), respectively. Chronic GVHD was observed in 13 of 26 patients (50.0%) and was extensive in 4 patients (15.4%). The probability that patients would attain 2-years overall survival (OS) was 76.3%. Conclusion Cotransplantation of haploidentical hematopoietic stem cells and UC-MSCs has good treatment effect to patients with SAA without HLA-identical sibling donors or unrelated donors, which is a feasible salvage approach.
出处 《解放军医学院学报》 CAS 2014年第12期1191-1195,共5页 Academic Journal of Chinese PLA Medical School
基金 全军医学科技青年培育项目(13QNP179)~~
关键词 造血干细胞移植 单倍体 间充质干细胞 再生障碍性贫血 hematopoietic stem cell transplantation haploid mesenchymal stem cells aplastic anemia
  • 相关文献

参考文献18

  • 1Wang HX, Yan HM, Duan LN, et al. Haploidentical hematopoietic stem cell transplantation in child hematologic malignancies with G-CSF-mobilized marrow grafts without T-cell depletion : a single- center report of 45 cases~ J ]. Pediatr Hematol Oncol, 2009, 26( 3 ): 119-128.
  • 2Fang B, Song Y, Li N, et al. Cotransplantation of haploidentical mesenchymal stem ceils to reduce the risk of graft failure in a patient with refractory severe aplastic anemia [ J ] . Acta Haematol, 2008, 119 ( 3 ) : 162-165.
  • 3Xu LP, Liu KY, Liu DH, et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia [ J ] . Bone Marrow Transplant, 2012, 47 ( 12 ) : 1507-1512.
  • 4Wang HX, Wang ZD, Zheng XL, et al. Hematopoietic stem celltransplantation with umbilical cord multipotent stromal cell infusion for the treatment of aplastic anemia-a single-center experience [ J ] . Cytotherapy, 2013, 15 ( 9 ) : 1118-1125.
  • 5Mo X, Huang X. Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation [ J ] . Front Med, 2013, 7 ( 3 ) : 306-315.
  • 6Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation : clinical outcomes and immune reconstitution [ J ] . J Clin Oncol, 2007, 25 ( 6 ) : 690- 697.
  • 7Bethge WA, Haegele M, Faul C, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion : fast engraftment and low toxicity [ J ] . Exp Hematol, 2006, 34 ( 12 ) : 1746-1752.
  • 8Passweg JR, P 6 rez WS, Eapen M, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia [ J ] . Bone Marrow Transplant, 2006, 37 ( 7 ) : 641-649.
  • 9Lu LL, Liu Y J, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem ceils with hematopoiesis- supportive function and other potentials [ J ] . Haematologica, 2006, 91 ( 8 ) : 1017-1026.
  • 10Ning H, Yang F, Jiang M, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients : outcome of a pilot clinical study [ J ] . Leukemia, 2008, 22 ( 3 ) : 593-599.

同被引文献93

  • 1Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagno- sis and management of aplastic anaemia [J]. Br J Haematol, 2009, 147( 1 ) :43-70. doi: 10.1111/j. 1365-2141.2009.07842.x.
  • 2Yagasaki H, Takahashi Y, Hama A, et al. Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastie anemia [J]. Bone Marrow Transplant, 2010, 45 (10):1508-1513. doi: 10.1038/bmt .2009.378.
  • 3Shin SH, Lee SE, Lee JW. Recent advances in treatment of aplastic anemia[J]. Korean J Intern Med, 2014, 29(6):713-726. doi: 10.3904/kjim.2014.29.6.713.
  • 4Bacigalupo A, Soci6 G, Hamladji RM, et al. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis [J]. Haematologica, 2015, 100( 5 ):696-702. doi: 10.3324/haematol.2014.115345.
  • 5Wagner JL, Deeg H J, Seidel K, et al. Bone marrow transplanta- tion for severe aplastic anemia from genotypically HLA-non- identical relatives. An update of the Seattle experience [J]. Transplantation, 1996, 61 ( 1 ):54-61.
  • 6Gao L, Li Y, Zhang Y, et al. Long-term outcome of HLA-haploi- dentical hematopoietic SCT without in vitro T-ceU depletion for adult severe aplastic anemia after modified conditioning and sup- portive therapy[J]. Bone Marrow Transplant, 2014, 49(4):519- 524. doi: 10.1038/bmt.2013.224.
  • 7Dulley FL, Vigorito AC, Aranha FJ, et al. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection [J]. Bone Marrow Transplant, 2004, 33 ( 1 ):9-13.
  • 8Bacigalupo A, Socie' G, Lanino E, et al. Fludarabine, cyclophos- phamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired se- vere aplastic anemia: a retrospective study from the EBMT-SAA Working Party [ J ]. Haematologica, 2010, 95 (6) :976- 982. doi: 10.3324/haematol.2009.018267.
  • 9Marsh JC, Gupta V, Lira Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia [J]. Blood, 2011, 118 (8):2351-2357. doi: 10.1182/ blood-2010-12-327536.
  • 10Wang Z, Zheng X, Yah H, et al. Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adoles- cents with acquired severe aplastic anemia [J]. Bone Marrow Transplant, 2014, 49 (12):1481-1485. doi: 10.1038/bmt. 2014.187.

引证文献18

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部